Mark D. Erion
Impact in
- Physiology top 0.2%
- Adenosine and Purinergic Signaling
- Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
Papers in
-
- Biochemical and Molecular Research 33
- Metabolism, Diabetes, and Cancer 10
-
- Synthesis and Biological Evaluation 11
- Co-authors
- M. Rami Reddy (22 shared papers)Paul D. van Poelje (28 shared papers)Scott J. Hecker (5 shared papers)S.E. Ealick (11 shared papers)Qun Dang (16 shared papers)Wayne C. Guida (11 shared papers)Srinivas Rao Kasibhatla (13 shared papers)Scott Potter (8 shared papers)
- Journals
- Journal of Medicinal Chemistry (25 papers)Journal of the American Chemical Society (12 papers)Biochemistry (7 papers)Journal of Computational Chemistry (6 papers)Journal of Pharmacology and Experimental Therapeutics (6 papers)
- Partner nations
- United StatesSwitzerlandSpain
In The Last Decade
Mark D. Erion
130 papers receiving 5.2k citations
Peers
Comparison fields: 5 of 127
- Physiology 587
- Infectious Diseases 763
- Organic Chemistry 1.3k
- Molecular Biology 2.9k
- Endocrinology, Diabetes and Metabolism 652
Countries citing papers authored by Mark D. Erion
This map shows the geographic impact of Mark D. Erion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Erion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Erion more than expected).
Fields of papers citing papers by Mark D. Erion
This network shows the impact of papers produced by Mark D. Erion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Erion. The network helps show where Mark D. Erion may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark D. Erion, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 131 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 323 | |
| 2 | 2007 | 192 | |
| 3 | 2008 | 172 | |
| 4 | 1998 | 167 | |
| 5 | 2001 | 160 | |
| 6 | 2010 | 142 | |
| 7 | 2005 | 140 | |
| 8 | 2004 | 126 | |
| 9 | 1991 | 126 | |
| 10 | Free energy calculations in rational drug design | 2001 | 115 |
| 11 | 1997 | 113 | |
| 12 | 2012 | 111 | |
| 13 | 1997 | 100 | |
| 14 | 1993 | 98 | |
| 15 | 2000 | 95 | |
| 16 | 2005 | 90 | |
| 17 | 1995 | 87 | |
| 18 | 1994 | 86 | |
| 19 | 2007 | 84 | |
| 20 | 1996 | 80 |
About Mark D. Erion
Mark D. Erion is a scholar working on Molecular Biology, Organic Chemistry, Physiology, Infectious Diseases and Oncology, having authored 131 papers that have together received 5.4k indexed citations. Recurring topics across this work include Biochemical and Molecular Research (33 papers), Adenosine and Purinergic Signaling (22 papers), HIV/AIDS drug development and treatment (20 papers), Cancer, Hypoxia, and Metabolism (13 papers), Synthesis and Biological Evaluation (11 papers), Metabolism, Diabetes, and Cancer (10 papers), Peptidase Inhibition and Analysis (10 papers) and Enzyme Structure and Function (9 papers). The work is most often cited by research in Physiology (587 citations), Infectious Diseases (763 citations), Organic Chemistry (1.3k citations), Molecular Biology (2.9k citations) and Endocrinology, Diabetes and Metabolism (652 citations). Mark D. Erion has collaborated with scholars based in United States, Switzerland and Spain. Frequent co-authors include M. Rami Reddy, Paul D. van Poelje, Scott J. Hecker, S.E. Ealick, Qun Dang, Wayne C. Guida, Srinivas Rao Kasibhatla, Scott Potter, Bheemarao G. Ugarkar and K. Raja Reddy. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of the American Chemical Society, Biochemistry, Journal of Computational Chemistry and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.